304 related articles for article (PubMed ID: 30373366)
21. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
[TBL] [Abstract][Full Text] [Related]
22. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells.
Skrott Z; Cvek B
Mini Rev Med Chem; 2012 Oct; 12(12):1184-92. PubMed ID: 22931589
[TBL] [Abstract][Full Text] [Related]
23. Improvement of Asparagine Ethylenediamines as Anti-malarial
Zhan W; Visone J; Ouellette T; Harris JC; Wang R; Zhang H; Singh PK; Ginn J; Sukenick G; Wong TT; Okoro JI; Scales RM; Tumwebaze PK; Rosenthal PJ; Kafsack BFC; Cooper RA; Meinke PT; Kirkman LA; Lin G
J Med Chem; 2019 Jul; 62(13):6137-6145. PubMed ID: 31177777
[TBL] [Abstract][Full Text] [Related]
24. Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B.
Reynolds JM; El Bissati K; Brandenburg J; Günzl A; Mamoun CB
BMC Clin Pharmacol; 2007 Oct; 7():13. PubMed ID: 17956613
[TBL] [Abstract][Full Text] [Related]
25. The proteasome as a target to combat malaria: hits and misses.
Krishnan KM; Williamson KC
Transl Res; 2018 Aug; 198():40-47. PubMed ID: 30009761
[TBL] [Abstract][Full Text] [Related]
26. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
[TBL] [Abstract][Full Text] [Related]
27. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.
Hu G; Lin G; Wang M; Dick L; Xu RM; Nathan C; Li H
Mol Microbiol; 2006 Mar; 59(5):1417-28. PubMed ID: 16468986
[TBL] [Abstract][Full Text] [Related]
28. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.
Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M
J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686
[TBL] [Abstract][Full Text] [Related]
29. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
[TBL] [Abstract][Full Text] [Related]
31. Urea-containing peptide boronic acids as potent proteasome inhibitors.
Han LQ; Yuan X; Wu XY; Li RD; Xu B; Cheng Q; Liu ZM; Zhou TY; An HY; Wang X; Cheng TM; Ge ZM; Cui JR; Li RT
Eur J Med Chem; 2017 Jan; 125():925-939. PubMed ID: 27769033
[TBL] [Abstract][Full Text] [Related]
32. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Zhang J; Shen L; Wang J; Luo P; Hu Y
Med Chem; 2014; 10(1):38-45. PubMed ID: 23676009
[TBL] [Abstract][Full Text] [Related]
34. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
[TBL] [Abstract][Full Text] [Related]
35. Development of Potent and Highly Selective Epoxyketone-Based Plasmodium Proteasome Inhibitors.
Almaliti J; Fajtová P; Calla J; LaMonte GM; Feng M; Rocamora F; Ottilie S; Glukhov E; Boura E; Suhandynata RT; Momper JD; Gilson MK; Winzeler EA; Gerwick WH; O'Donoghue AJ
Chemistry; 2023 Apr; 29(20):e202203958. PubMed ID: 36617500
[TBL] [Abstract][Full Text] [Related]
36. High-resolution cryo-EM proteasome structures in drug development.
Morris EP; da Fonseca PCA
Acta Crystallogr D Struct Biol; 2017 Jun; 73(Pt 6):522-533. PubMed ID: 28580914
[TBL] [Abstract][Full Text] [Related]
37. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
[TBL] [Abstract][Full Text] [Related]
38. Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors.
Garg S; Kreutzfeld O; Chelebieva S; Tumwebaze PK; Byaruhanga O; Okitwi M; Orena S; Katairo T; Nsobya SL; Conrad MD; Aydemir O; Legac J; Gould AE; Bayles BR; Bailey JA; Duffey M; Lin G; Kirkman LA; Cooper RA; Rosenthal PJ
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0081722. PubMed ID: 36094216
[TBL] [Abstract][Full Text] [Related]
39. Rational Design of Proteasome Inhibitors as Antimalarial Drugs.
Le Chapelain C; Groll M
Angew Chem Int Ed Engl; 2016 May; 55(22):6370-2. PubMed ID: 27079849
[TBL] [Abstract][Full Text] [Related]
40. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
